Lercanidipine/enalapril fixed combination

Meir Medical Center · FDA-approved active Small molecule

Lercanidipine/enalapril fixed combination is a Calcium channel blocker / ACE inhibitor combination Small molecule drug developed by Meir Medical Center. It is currently FDA-approved for Hypertension. Also known as: Vasodip Combo 20, hypertension, ambulatory blood pressure monitoring.

This fixed combination reduces blood pressure by blocking calcium channels in vascular smooth muscle (lercanidipine) and inhibiting angiotensin-converting enzyme (enalapril).

This fixed combination reduces blood pressure by blocking calcium channels in vascular smooth muscle (lercanidipine) and inhibiting angiotensin-converting enzyme (enalapril). Used for Hypertension.

At a glance

Generic name	Lercanidipine/enalapril fixed combination
Also known as	Vasodip Combo 20, hypertension, ambulatory blood pressure monitoring
Sponsor	Meir Medical Center
Drug class	Calcium channel blocker / ACE inhibitor combination
Target	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

Lercanidipine is a dihydropyridine calcium channel blocker that prevents calcium influx into vascular smooth muscle cells, causing vasodilation. Enalapril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Together, these complementary mechanisms provide synergistic antihypertensive effects.

Approved indications

• Hypertension

Common side effects

• Headache
• Dizziness
• Peripheral edema
• Cough
• Fatigue
• Hypotension

Key clinical trials

• Antihypertensive Efficacy of Fixed Combination Drug (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Lercanidipine/enalapril fixed combination CI brief — competitive landscape report
• Lercanidipine/enalapril fixed combination updates RSS · CI watch RSS
• Meir Medical Center portfolio CI

Frequently asked questions about Lercanidipine/enalapril fixed combination

What is Lercanidipine/enalapril fixed combination?

Lercanidipine/enalapril fixed combination is a Calcium channel blocker / ACE inhibitor combination drug developed by Meir Medical Center, indicated for Hypertension.

How does Lercanidipine/enalapril fixed combination work?

This fixed combination reduces blood pressure by blocking calcium channels in vascular smooth muscle (lercanidipine) and inhibiting angiotensin-converting enzyme (enalapril).

What is Lercanidipine/enalapril fixed combination used for?

Lercanidipine/enalapril fixed combination is indicated for Hypertension.

Who makes Lercanidipine/enalapril fixed combination?

Lercanidipine/enalapril fixed combination is developed and marketed by Meir Medical Center (see full Meir Medical Center pipeline at /company/meir-medical-center).

Is Lercanidipine/enalapril fixed combination also known as anything else?

Lercanidipine/enalapril fixed combination is also known as Vasodip Combo 20, hypertension, ambulatory blood pressure monitoring.

What drug class is Lercanidipine/enalapril fixed combination in?

Lercanidipine/enalapril fixed combination belongs to the Calcium channel blocker / ACE inhibitor combination class. See all Calcium channel blocker / ACE inhibitor combination drugs at /class/calcium-channel-blocker-ace-inhibitor-combination.

What development phase is Lercanidipine/enalapril fixed combination in?

Lercanidipine/enalapril fixed combination is FDA-approved (marketed).

What are the side effects of Lercanidipine/enalapril fixed combination?

Common side effects of Lercanidipine/enalapril fixed combination include Headache, Dizziness, Peripheral edema, Cough, Fatigue, Hypotension.

What does Lercanidipine/enalapril fixed combination target?

Lercanidipine/enalapril fixed combination targets L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE) and is a Calcium channel blocker / ACE inhibitor combination.

Related

• Drug class: All Calcium channel blocker / ACE inhibitor combination drugs
• Target: All drugs targeting L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
• Manufacturer: Meir Medical Center — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for Hypertension
• Also known as: Vasodip Combo 20, hypertension, ambulatory blood pressure monitoring